Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

FDA Grants Orphan Drug Designation to Osemitamab for Pancreatic Cancer

April 10th 2023

The FDA has granted an orphan drug designation to osemitamab for the treatment of patients with pancreatic cancer, marking the second ODD for the agent following its initial designation in 2021 for use in those with gastric and gastroesophageal junction cancer.

Closing Thoughts on Advanced HCC and Highlights from ASCO GI 2023

April 10th 2023

Closing out this discussion, experts share their final thoughts on advanced HCC treatments and key data presented at the 2023 ASCO Gastrointestinal Cancers Symposium.

Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer: Patient-Derived Organoids

April 7th 2023

In this second episode of OncChats: Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Richard Burkhart, MD, provide an overview of patient-derived organoids and pharmacotyping in locally advanced pancreatic cancer.

Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer: Role of the Gastroenterologist

April 6th 2023

In this first episode of OncChats: Taking Organoids From Bench to Bedside Through Endoscopy in Pancreatic Cancer, Toufic A. Kachaamy, MD, Madappa Kundranda, MD, PhD, and Richard Burkhart, MD, discuss the involvement of the gastroenterologist from diagnosis to palliative care in the management of patients with pancreatic cancer.

Dr Dawson on Palliative Radiotherapy in Symptomatic HCC or Liver Metastases

April 5th 2023

Laura Dawson, MD, FRCPC, discusses the investigation of palliative radiotherapy for patients with symptomatic hepatocellular carcinoma or liver metastases.

Understanding Endoscopy in the Realm of GI Cancers: An Evolving Field

April 5th 2023

In this seventh episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, discuss the convergence of gastroenterology and interventional gastroenterology in gastrointestinal cancer management and the future of interventional endoscopy.

FDA Accepts BLA for Trastuzumab Biosimilar in HER2+ Breast Cancer, Gastric/GEJ Cancer

April 5th 2023

The FDA has accepted a biologics license application for the HLX02, a proposed trastuzumab biosimilar, as adjuvant therapy for patients with HER2-overexpressing breast cancer, HER2-overexpressing metastatic breast cancer, and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma

Dr Hays on the Evolution of the Treatment Landscape in HCC

April 4th 2023

John L. Hays, MD, PhD, discusses the evolution of treating patients with hepatocellular carcinoma.

Management of Child-Pugh B Patients with Advanced HCC

April 3rd 2023

Oncologists provide an overview of the treatment management of Child-Pugh B patients with advanced HCC.

Treatment Considerations for Advanced HCC in Second Line and Beyond

April 3rd 2023

In this discussion, panelists outline treatment considerations for patients with advanced HCC in the 2L setting and beyond.

Understanding Endoscopy in the Realm of GI Cancers: Efforts to Advance the Field

March 31st 2023

In this sixth episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, share efforts to increase awareness around endoscopy in gastrointestinal cancer.

FDA Grants Fast Track Designation to PBP1510 in Metastatic Pancreatic Adenocarcinoma

March 31st 2023

The FDA has granted a fast track designation to PBP1510 (ulenistamab) for the treatment of patients with unresectable or metastatic pancreatic adenocarcinoma that has relapsed following and/or is refractory to at least 1 prior line therapy.

Dr Malalur on the Implications of NALIRIFOX in Pancreatic Ductal Adenocarcinoma

March 29th 2023

Pannaga G. Malalur, MBBS, discusses the implications of the findings for the use of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin in the frontline setting for patients with metastatic pancreatic ductal adenocarcinoma.

Understanding Endoscopy in the Realm of GI Cancers: Endoscopic Oncology and Existing Barriers

March 29th 2023

In this fifth episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, review the potential role for endoscopic ablation in gastrointestinal cancer.

Systemic Immunotherapies for Advanced HCC in Second Line and Beyond

March 27th 2023

In the context of frontline treatment strategies in advanced HCC, expert oncologists review clinical research in systemic immunotherapy approaches.

Anti-Angiogenic Systemic Therapies for Advanced HCC in Second Line and Beyond

March 27th 2023

Expert panelists highlight anti-angiogenic systemic therapies under investigation for advanced HCC in second line and beyond.

Dr Hill on Efficacy of Dostarlimab in dMMR Locally Advanced Rectal Cancer

March 24th 2023

Joshua Hill, MD, MS, discussed the early efficacy of dostarlimab in mismatch repair–deficient locally advanced rectal cancer.

Understanding Endoscopy in the Realm of GI Cancers: Endoscopic Cancer Resection

March 24th 2023

In this fourth episode of OncChats: Understanding Endoscopy in the Realm of GI Cancers, Madappa Kundranda, MD, PhD, and Toufic A. Kachaamy, MD, provide insight on the use of endoscopic submucosal resection and endoscopic evaluation for tumor response as it pertains to organ preservation in gastrointestinal cancer.

Research Clarifies Treatment Patterns and Raises New Questions Across GI Cancers

March 23rd 2023

Jimmy Hwang, MD, discusses findings supporting the use of immunotherapy in hepatocellular carcinoma and biliary tract cancer, the potential benefits of antibody-drug conjugates in metastatic colorectal cancer, and unmet needs in esophageal squamous cell carcinoma and rectal cancer.

First-line Zolbetuximab Plus CAPOX Prolongs Survival in CLDN18.2+/HER2– Unresectable Locally Advanced or Metastatic Gastric/GEJ Adenocarcinoma

March 22nd 2023

The addition of zolbetuximab to CAPOX led to a statistically significant improvement in progression-free survival and overall survival compared with placebo plus CAPOX for patients with Claudin-18.2–positive/HER2-negative, unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.